Scientists have discovered why fetal muscle stem cells are better at regenerating muscle than adult muscle stem cells. These findings open new avenues for the treatment of muscular dystrophies. Researchers from Sanford Burnham Prebys Medical Discovery Institute, based in La Jolla, California, and Orlando, Florida, investigated the properties of different cells in a study…
News
Tens of thousands of businesses across the U.S. are participating in this year’s 34th annual Muscular Dystrophy Association (MDA) Shamrocks campaign to raise funds for research and support programs to help people with muscular dystrophy, amyotrophic lateral sclerosis (ALS), and other diseases that severely weaken muscle…
The Precision Medicine Initiative was launched in 2015 to spur biomedical research and the development of a more personalized approach to therapy, one based on an individual’s genetic profile and response to treatment. While the initiative largely focuses on genetically based cancers, a University of Wisconsin-Madison review points out that Emery–Dreifuss muscular…
Ways of better addressing the high cost of breakthrough treatments that either are or might soon be available for a range of chronic and rare diseases, from certain cancers to Duchenne muscular dystrophy (DMD) or Becker’s muscular dystrophy (BMD), was the subject of recent research — with the authors suggesting that healthcare…
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, has treated the first Duchenne muscular dystrophy patient with related cardiomyopathy with its drug candidate CAP-1002, and is continuing to enroll people in its HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) Phase I/II clinical trial (ClinicalTrials.gov Identifier: NCT02485938). CAP-1002 is a proprietary allogeneic,…
PTC Therapeutics, Inc. announced Wednesday that it has received a Refuse to File letter from the U.S. Food and Drug Administration (FDA) with regard to its New Drug Application (NDA) for ataluren (trade name, Translarna), an oral, first-in-class, protein restoration therapy for the treatment of nonsense mutation Duchenne muscular dystrophy…
One hundred and nine members of the U.S. House of Representatives signed a letter to the U.S. Food and Drug Administration (FDA) calling for the agency to immediately increase efforts to mobilize all available tools, resources, and authorities to advance new and more effective treatments for Duchenne muscular dystrophy. The bipartisan appeal…
Tarix Orphan LLC recently announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to TXA127, the company’s lead candidate for the treatment of laminin-deficient congenital muscular dystrophy (LAMA2 MD). Early-onset LAMA2-related muscular dystrophy (MD) occurs in nearly one in every 30,000 people and is responsible for…
Pfizer, in collaboration with Newcastle University, reports finding four serum biomarkers for three types of muscular dystrophy. The markers may be valuable for monitoring disease progression and treatment response in both preclinical and clinical studies. Researchers analyzed previously collected serum samples from three types of muscular dystrophies — 38 Becker muscular dystrophy (BMD) and…
UCLA scientists have developed a potential gene therapy approach for Duchenne muscular dystrophy (DMD) using CRISPR/Cas9 technology and stem cells. If the new treatment proves successful and reaches the clinic — possibly in the next decade — it could be applied to 60 percent of all Duchenne patients. CRISPR/Cas9 is a gene-editing technology that allows targeting and…
Recent Posts
- I have new criteria for when my sons participate in DMD clinical trials
- New gene therapy for OPMD shows lasting success in small US trial
- How art fosters a sense of belonging in my life with Duchenne
- First boys dosed in Phase 2 trial of oral DMD treatment SAT-3247
- Guest Voice: Despite losses from Duchenne MD, I persevere